This is a synthetic peptide designed for use in combination with anti-SH2D1A Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
SH2D1A
(SH2 Domain Containing 1A (SH2D1A))
Hintergrund
SH2D1A is a protein that plays a major role in the bidirectional stimulation of T and B cells. It associates with the signaling lymphocyte-activation molecule, thereby acting as an inhibitor of this transmembrane protein by blocking the recruitment of the SH2-domain-containing signal-transduction molecule SHP-2 to its docking site. This protein can also bind to other related surface molecules that are expressed on activated T, B and NK cells, thereby modifying signal transduction pathways in these cells. Mutations in SH2D1A gene cause lymphoproliferative syndrome X-linked type 1 or Duncan disease, a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus, with symptoms including severe mononucleosis and malignant lymphoma.
Protein Interaction Partner: CD244,CD84,LY9,SLAMF1,SLAMF1,ARHGEF6,ARHGEF7,CD84,DOK1,FYB,FYN,GRB2,LCK,LY9,SLAMF1,SLAMF6,SLAMF7,CD244,CD84,DOK1,FYN,LY9,SLAMF1,SLAMF6